Biotech News
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
ir.cytomx.com2026-05-07 20:20 EST
- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in Varseta-M Dose Optimization completed; data update expected in 2H 2026 to inform monotherapy dose